China/Asia TMT

Shawn Yang

China growth and global non-US Internet equities

Blue Lotus Research Institute

Blue Lotus Research is a Hong Kong Type 4 Licensed investment advisory firm focusing on Chinese growth equities and global non-US Internet equities

Thematic (Sector/Industry)

<ul>
<li>Shein/PDD: Our check and local media reports of Shein's newly-launched marketplace, and implication to PDD (-)</li>
<li>PDD/700.HK/BABA/JD: China major Ecommerce platform's low price strategy in 6/18 promotion (-/+/+/+)</li>
<li>ZLAB：ZLAB revenue met our expectation while loss greatly beat our expectation on reduced R&amp;D</li>
</ul>


Shein/PDD: Our check and local media reports of Shein's newly-launched marketplace, and implication to PDD (-)
PDD/700.HK/BABA/JD: China major Ecommerce platform's low price strategy in 6/18 promotion (-/+/+/+)
ZLAB：ZLAB revenue met our expectation while loss greatly beat our expectation on reduced R&amp;D


China TMT Update (May.12) - Shein/PDD/700.HK/BABA/JD/ZLAB:Shein's Newly-Launched Marketplace

Equity Bottom-Up

<ul>
<li>Zai Lab (ZLAB) reported C1Q23 top line in-line with our estimate but operating/net loss much smaller than our estimate due to cut in R&amp;D spending. </li>
<li>ZLAB’s narrower losses in C4Q22 and C1Q23, achieved through R&amp;D cut, do demonstrate the viability of the company achieving commercial breakeven by 2023 and full breakeven by 2025. </li>
<li>We still think these viabilities have difficulties to achieve and even achieved, hurt the LT value of the company; We raised our TP from US$25 to US$29 but maintain SELL.</li>
</ul>


Zai Lab (ZLAB) reported C1Q23 top line in-line with our estimate but operating/net loss much smaller than our estimate due to cut in R&amp;D spending. 
ZLAB’s narrower losses in C4Q22 and C1Q23, achieved through R&amp;D cut, do demonstrate the viability of the company achieving commercial breakeven by 2023 and full breakeven by 2025. 
We still think these viabilities have difficulties to achieve and even achieved, hurt the LT value of the company; We raised our TP from US$25 to US$29 but maintain SELL.


[Zai LAB (ZLAB US) Target Price Change]: Demonstrating Directionally Business Model to Profit

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

<ul>
<li>It is the time to reassess the commercialization performance and the outlook of China biotech companies, including BeiGene, Innovent, Henlus, Zai Lab, Hutchmed, Junshi, RemeGen, Innocare, Akeso. </li>
<li>We summarized the data of these biotech companies’ product revenue and profit performance to judge whether their commercialization capability is sufficient to afford production, sales teams and long-term R&amp;D activities. </li>
<li>Most China Biotech cannot be said to achieve "commercialization success", but they have showed some difference.We hope investors could have a better understanding about China biotech and make better decisions. </li>
</ul>


It is the time to reassess the commercialization performance and the outlook of China biotech companies, including BeiGene, Innovent, Henlus, Zai Lab, Hutchmed, Junshi, RemeGen, Innocare, Akeso. 
We summarized the data of these biotech companies’ product revenue and profit performance to judge whether their commercialization capability is sufficient to afford production, sales teams and long-term R&amp;D activities. 
Most China Biotech cannot be said to achieve "commercialization success", but they have showed some difference.We hope investors could have a better understanding about China biotech and make better decisions. 


China Biotech – The Commercialization Performance and The Outlook

<ul>
<li>LKNCY: Luckin Coffee launch new flavor Mint Coconut latte, and co-brand with Doraemon, but with no expectation to be the next blockbuster(+)</li>
<li>BGNE/9969HK:Abbview &amp; J&amp;J voluntarily withdrew two major indication of IMBRUVICA, a known positive to BeiGene but within our expectations (+)</li>
<li>ZLAB: GSK's court battle loss to AZ likely will not affect Zai Lab's royalty obligation on Zejula (/)</li>
</ul>


LKNCY: Luckin Coffee launch new flavor Mint Coconut latte, and co-brand with Doraemon, but with no expectation to be the next blockbuster(+)
BGNE/9969HK:Abbview &amp; J&amp;J voluntarily withdrew two major indication of IMBRUVICA, a known positive to BeiGene but within our expectations (+)
ZLAB: GSK's court battle loss to AZ likely will not affect Zai Lab's royalty obligation on Zejula (/)


China TMT Update(Apr.12/Pt2)-LKNCY/BGNE/9969HK/ZLAB - Abbview & J&J Voluntarily Withdrew

<ul>
<li>700.HK/ IQ： Tencent Video and Douyin reach strategic cooperation （+/-）</li>
<li>NIO: NIO to allow consumers to lock in EC7 orders starting Apr 10 （+）</li>
<li>ZLAB/1801HK: ZaiLab started FGFR2 mAb Phase III trial for Gastric Cancer in China (+)</li>
</ul>


700.HK/ IQ： Tencent Video and Douyin reach strategic cooperation （+/-）
NIO: NIO to allow consumers to lock in EC7 orders starting Apr 10 （+）
ZLAB/1801HK: ZaiLab started FGFR2 mAb Phase III trial for Gastric Cancer in China (+)


China TMT Update(Apr.10): 700.HK/IQ/NIO/ZLAB/1801HK - Tencent Video and Douyin Reach Cooperation

China

Zai Lab Limited operates as a bio-pharmaceutical company. The Company researches and develops therapeutic technology for antibody-based oncology, autoimmune, and infectious diseases treatments. Zai Lab also manufactures drugs in the form of capsules, injections, and liquids. Zai Lab serves patients worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Zai Lab Ltd (ZLAB US)

China TMT Update (May.12) - Shein/PDD/700.HK/BABA/JD/ZLAB:Shein's Newly-Launched Marketplace

Shein's newly-launched marketplace、China major Ecommerce platform's low price strategy in 6/18 promotion，ZLAB revenue met our expectation while...

Blue Lotus Research Institute

[Zai LAB (ZLAB US) Target Price Change]: Demonstrating Directionally Business Model to Profit

Zai Lab (ZLAB) reported C1Q23 top line in-line with our estimate but operating/net loss much smaller than our estimate due to cut in R&D spending...

Blue Lotus Research Institute

China Biotech – The Commercialization Performance and The Outlook

In the context of the fading dividend of medical system reform and the lack of next big variety, the previous wave of innovative drug boom is hard...

Xinyao (Criss) Wang

China TMT Update(Apr.12/Pt2)-LKNCY/BGNE/9969HK/ZLAB - Abbview & J&J Voluntarily Withdrew

Luckin Coffee launch new flavor Mint Coconut latte(+); Abbview & J&J voluntarily withdrew two major indication of IMBRUVICA(+); ZLAB: GSK's court...

Blue Lotus Research Institute

China TMT Update(Apr.10): 700.HK/IQ/NIO/ZLAB/1801HK - Tencent Video and Douyin Reach Cooperation

Tencent Video and Douyin reach strategic cooperation ； NIO to allow onsumers to lock in EC7 orders starting Apr 10 ；ZaiLab started FGFR2 mAb Phase...

Blue Lotus Research Institute

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)